OpenLB
Open Library of Bioscience
Advanced Search
Epigenomics
Jan, 2025;17 (1): 59-74.

Cancer epigenetic therapy: recent advances, challenges, and emerging opportunities.

Rajita Vatapalli, Alex P Rossi, Ho Man Chan, Jingwen Zhang
Author Information
  1. Rajita Vatapalli: AstraZeneca, Oncology Research and Development, Waltham, MA, USA.
  2. Alex P Rossi: AstraZeneca, Oncology Research and Development, Waltham, MA, USA.
  3. Ho Man Chan: AstraZeneca, Oncology Research and Development, Waltham, MA, USA.
  4. Jingwen Zhang: AstraZeneca, Oncology Research and Development, Waltham, MA, USA. ORCID
PMID: 39601374 DOI: 10.1080/17501911.2024.2430169

Abstract

Epigenetic dysregulation is an important nexus in the development and maintenance of human cancers. This review provides an overview of how understanding epigenetic dysregulation in cancers has led to insights for novel cancer therapy development. Over the past two decades, significant strides have been made in drug discovery efforts targeting cancer epigenetic mechanisms, leading to successes in clinical development and approval of cancer epigenetic therapeutics. This article will discuss the current therapeutic rationale guiding the discovery and development of epigenetic therapeutics, key learnings from clinical experiences and new opportunities on the horizon.

Keywords

Cancer epigenetics DNA modifications drug combination drug discovery histone modifications synthetic lethality

References

  1. Nat Med. 2014 Mar;20(3):251-4 [PMID: 24562383]
  2. Transl Oncol. 2022 Feb;16:101312 [PMID: 34922087]
  3. Cell. 2017 Jul 27;170(3):577-592.e10 [PMID: 28753431]
  4. Oncogene. 2008 Apr 3;27(15):2237-42 [PMID: 17934517]
  5. Nat Rev Drug Discov. 2012 Apr 13;11(5):384-400 [PMID: 22498752]
  6. Nat Med. 2015 Nov;21(11):1344-9 [PMID: 26437366]
  7. Cell Rep. 2018 Dec 4;25(10):2808-2820.e4 [PMID: 30517868]
  8. Nat Commun. 2020 Nov 3;11(1):5551 [PMID: 33144586]
  9. Nat Rev Cancer. 2011 Sep 23;11(10):726-34 [PMID: 21941284]
  10. EMBO J. 2017 May 2;36(9):1243-1260 [PMID: 28320739]
  11. Sci Adv. 2021 Jul 14;7(29): [PMID: 34261657]
  12. Cold Spring Harb Perspect Med. 2016 Oct 3;6(10): [PMID: 27599530]
  13. Cancer Cell. 2019 Oct 14;36(4):385-401.e8 [PMID: 31564637]
  14. Expert Opin Ther Pat. 2024 Mar;34(3):159-169 [PMID: 38578210]
  15. Jpn J Clin Oncol. 2022 Sep 18;52(9):1014-1020 [PMID: 35649345]
  16. Hematology Am Soc Hematol Educ Program. 2011;2011:354-60 [PMID: 22160057]
  17. Front Immunol. 2022 Jan 24;13:809761 [PMID: 35140720]
  18. Nat Rev Genet. 2017 Oct;18(10):613-623 [PMID: 28649135]
  19. Cancer Res. 2018 Feb 15;78(4):938-949 [PMID: 29259010]
  20. Oncotarget. 2017 Jun 27;8(26):43295-43305 [PMID: 28476038]
  21. Nat Cancer. 2021 Oct;2(10):1002-1017 [PMID: 34790902]
  22. Cell. 2017 Jun 29;170(1):142-157.e19 [PMID: 28648661]
  23. Clin Pharmacol Ther. 2010 May;87(5):543-52 [PMID: 20237469]
  24. Oncogene. 2018 Apr;37(15):1949-1960 [PMID: 29367755]
  25. Leukemia. 2014 Sep;28(9):1774-83 [PMID: 24699305]
  26. Cold Spring Harb Perspect Biol. 2014 Apr 01;6(4):a018713 [PMID: 24691964]
  27. Cell. 2018 Apr 5;173(2):371-385.e18 [PMID: 29625053]
  28. Cancer Cell. 2011 Jul 12;20(1):53-65 [PMID: 21741596]
  29. Cancer Discov. 2023 May 4;13(5):1116-1143 [PMID: 36862804]
  30. Clin Cancer Res. 2021 Feb 15;27(4):1019-1028 [PMID: 33203644]
  31. Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98 [PMID: 17428177]
  32. Cells. 2020 Dec 21;9(12): [PMID: 33371192]
  33. Science. 2001 Aug 10;293(5532):1074-80 [PMID: 11498575]
  34. Cancer Cell. 2023 Jan 9;41(1):7-9 [PMID: 36459996]
  35. Expert Opin Ther Pat. 2022 May;32(5):507-522 [PMID: 35202550]
  36. Cell. 2010 Apr 2;141(1):69-80 [PMID: 20371346]
  37. Nat Commun. 2024 May 21;15(1):4327 [PMID: 38773088]
  38. Science. 2017 Jan 6;355(6320):78-83 [PMID: 28059767]
  39. Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3128-33 [PMID: 24520176]
  40. Cancer Res. 2016 Apr 1;76(7):1683-9 [PMID: 26988985]
  41. Prog Drug Res. 2011;67:v-viii [PMID: 21141721]
  42. Nature. 2012 Dec 6;492(7427):108-12 [PMID: 23051747]
  43. Nat Rev Drug Discov. 2020 Jan;19(1):23-38 [PMID: 31712683]
  44. Front Pharmacol. 2022 Dec 16;13:1072651 [PMID: 37077808]
  45. Biosci Rep. 2022 Apr 29;42(4): [PMID: 35438143]
  46. Anticancer Res. 2013 Aug;33(8):2989-96 [PMID: 23898051]
  47. Mol Cell. 2010 Jun 25;38(6):853-63 [PMID: 20541448]
  48. Blood. 2009 Jun 18;113(25):6403-10 [PMID: 19372255]
  49. J Biol Chem. 2019 Jun 21;294(25):9911-9923 [PMID: 31085587]
  50. Science. 2008 Sep 26;321(5897):1807-12 [PMID: 18772396]
  51. Experientia. 1964 Apr 15;20(4):202-3 [PMID: 5322617]
  52. Acta Pharm Sin B. 2024 Feb;14(2):533-578 [PMID: 38322348]
  53. Cancer Res. 2023 Aug 1;83(15):2584-2599 [PMID: 37249603]
  54. Oncogene. 2005 Aug 18;24(35):5471-81 [PMID: 16007216]
  55. Cancer Discov. 2016 Apr;6(4):430-45 [PMID: 26603525]
  56. Nature. 2014 Jan 23;505(7484):495-501 [PMID: 24390350]
  57. Trends Genet. 2020 Dec;36(12):936-950 [PMID: 32873422]
  58. Oncogene. 2007 Aug 13;26(37):5310-8 [PMID: 17694074]
  59. Cancer Cell. 2023 Jan 9;41(1):70-87.e14 [PMID: 36332625]
  60. Neuro Oncol. 2013 Feb;15(2):149-60 [PMID: 23190500]
  61. Nat Commun. 2022 Oct 10;13(1):5969 [PMID: 36216795]
  62. Mutat Res. 2008 Dec 1;647(1-2):21-9 [PMID: 18723033]
  63. Cell Rep. 2016 Apr 19;15(3):574-587 [PMID: 27068473]
  64. Science. 2016 Mar 11;351(6278):1214-8 [PMID: 26912360]
  65. Bioorg Med Chem Lett. 2022 May 1;63:128653 [PMID: 35257896]
  66. Nat Commun. 2020 Aug 19;11(1):4153 [PMID: 32814769]
  67. Oncotarget. 2014 Feb 15;5(3):587-98 [PMID: 24583822]
  68. ACS Cent Sci. 2023 Apr 11;9(5):915-926 [PMID: 37252349]
  69. Nat Chem Biol. 2012 Nov;8(11):890-6 [PMID: 23023262]
  70. J Pathol Transl Med. 2021 Mar;55(2):145-153 [PMID: 33677955]
  71. Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):87-92 [PMID: 11134513]
  72. Sci Adv. 2015 Jun 12;1(5):e1500447 [PMID: 26601204]
  73. Cancer Immunol Res. 2018 Dec;6(12):1561-1577 [PMID: 30341213]
  74. J Antibiot (Tokyo). 1984 Nov;37(11):1333-43 [PMID: 6511660]
  75. Blood. 2013 Aug 8;122(6):1017-25 [PMID: 23801631]
  76. Nature. 2002 Oct 10;419(6907):624-9 [PMID: 12374981]
  77. Nat Genet. 2023 Dec;55(12):2039-2048 [PMID: 38036785]
  78. PLoS One. 2016 Jul 08;11(7):e0158888 [PMID: 27391784]
  79. Br J Clin Pharmacol. 2021 Dec;87(12):4577-4597 [PMID: 33971031]
  80. Oncogene. 2017 May 18;36(20):2910-2918 [PMID: 27893709]
  81. Cell Death Dis. 2021 Mar 24;12(4):311 [PMID: 33762579]
  82. Cancer Sci. 2020 Mar;111(3):774-782 [PMID: 31955490]
  83. Sci Transl Med. 2021 Nov 17;13(620):eabh0272 [PMID: 34788079]
  84. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2989-94 [PMID: 22323599]
  85. Cancer Discov. 2013 Sep;3(9):1002-19 [PMID: 23955273]
  86. Curr Biol. 2002 Jun 25;12(12):1052-8 [PMID: 12123582]
  87. Cell Rep. 2022 Apr 12;39(2):110636 [PMID: 35417719]
  88. Mol Cancer Res. 2022 Jan;20(1):11-29 [PMID: 34389691]
  89. Cell. 2007 Feb 23;128(4):683-92 [PMID: 17320506]
  90. Heliyon. 2024 Jan 13;10(2):e24457 [PMID: 38312620]
  91. Nat Rev Cancer. 2020 Dec;20(12):743-756 [PMID: 33033407]
  92. Int J Cancer. 2008 Jul 1;123(1):8-13 [PMID: 18425818]
  93. Blood. 1998 Nov 1;92(9):3025-34 [PMID: 9787135]
  94. Science. 2017 Mar 17;355(6330):1147-1152 [PMID: 28302822]
  95. Nature. 2018 Mar 15;555(7696):371-376 [PMID: 29489755]
  96. Blood. 2011 Feb 24;117(8):2451-9 [PMID: 21190999]
  97. Science. 2016 Mar 11;351(6278):1208-13 [PMID: 26912361]
  98. Life Sci. 2022 Nov 1;308:120946 [PMID: 36096240]
  99. Ann Transl Med. 2023 Dec 20;11(12):409 [PMID: 38213803]
  100. J Med Chem. 2023 Aug 10;66(15):10761-10781 [PMID: 37523716]
  101. Front Pharmacol. 2022 Sep 02;13:932914 [PMID: 36120308]
  102. J Hematol Oncol. 2022 Mar 24;15(1):35 [PMID: 35331314]
  103. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7 [PMID: 23620515]
  104. Hematol Rep. 2024 Apr 18;16(2):244-254 [PMID: 38651453]
  105. J Am Chem Soc. 2013 Jan 16;135(2):669-82 [PMID: 23210835]
  106. Cancer Discov. 2016 Oct;6(10):1166-1181 [PMID: 27535106]
  107. Semin Cancer Biol. 2020 Oct;65:99-113 [PMID: 31877341]
  108. Science. 2012 Dec 14;338(6113):1465-9 [PMID: 23239736]
  109. Trends Cancer. 2020 Jul;6(7):580-592 [PMID: 32610068]
  110. Cancer Res. 2015 Sep 15;75(18):3865-3878 [PMID: 26139243]
  111. Nature. 2019 Nov;575(7781):210-216 [PMID: 31645765]
  112. EMBO J. 1995 May 15;14(10):2333-40 [PMID: 7539744]
  113. Leukemia. 2011 Apr;25(4):726-9 [PMID: 21233829]
  114. Nat Genet. 2013 Nov;45(11):1386-91 [PMID: 24076604]
  115. Mol Cell. 2011 Nov 18;44(4):609-20 [PMID: 22099308]
  116. Mol Cell. 2023 Apr 20;83(8):1216-1236.e12 [PMID: 36944333]
  117. Cancer Cell. 2015 Apr 13;27(4):431-3 [PMID: 25873167]
  118. Cell. 2017 Nov 30;171(6):1284-1300.e21 [PMID: 29195073]
  119. Blood. 2019 Jan 3;133(1):7-17 [PMID: 30361262]
  120. Oncogene. 2007 Aug 13;26(37):5395-407 [PMID: 17694081]
  121. Clin Epigenetics. 2021 Apr 7;13(1):71 [PMID: 33827674]
  122. Cancer Discov. 2023 Oct 5;13(10):2131-2149 [PMID: 37712571]
  123. Cancer Cell. 2019 Dec 9;36(6):660-673.e11 [PMID: 31821784]
  124. Trends Immunol. 2020 Oct;41(10):948-963 [PMID: 32976740]
  125. Drugs. 2020 Apr;80(5):513-521 [PMID: 32166598]
  126. Prog Drug Res. 2011;67:175-95 [PMID: 21141730]
  127. Cell. 2013 Mar 28;153(1):38-55 [PMID: 23540689]
  128. Cancer Cell. 2010 Oct 19;18(4):316-28 [PMID: 20951942]
  129. Nat Rev Cancer. 2019 Mar;19(3):151-161 [PMID: 30723290]
  130. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5 [PMID: 23236167]
  131. Cancer Res. 2013 Sep 1;73(17):5508-18 [PMID: 23872584]
  132. Nat Commun. 2022 Nov 10;13(1):6814 [PMID: 36357397]
  133. Cureus. 2020 May 25;12(5):e8273 [PMID: 32467817]
  134. Cell. 1980 May;20(1):85-93 [PMID: 6156004]
  135. Mol Cell Oncol. 2015 Apr 14;3(1):e1032476 [PMID: 27308548]
  136. Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:187-207 [PMID: 28992434]
  137. Nat Chem Biol. 2010 Mar;6(3):238-243 [PMID: 20139990]
  138. Nat Rev Genet. 2014 Apr;15(4):259-71 [PMID: 24614311]
  139. Nature. 2007 May 24;447(7143):396-8 [PMID: 17522671]
  140. Cancer Cell. 2023 Aug 14;41(8):1516-1534.e9 [PMID: 37541244]
  141. Nat Methods. 2018 Jun;15(6):407 [PMID: 29855579]
  142. Cell. 2017 Jul 27;170(3):564-576.e16 [PMID: 28753430]
  143. Cancer Discov. 2022 Jan;12(1):31-46 [PMID: 35022204]
  144. J Biomed Sci. 2023 Jul 31;30(1):60 [PMID: 37525190]
  145. Cell Chem Biol. 2020 Jan 16;27(1):41-46.e17 [PMID: 31786184]
  146. Front Pediatr. 2017 Feb 09;5:4 [PMID: 28232907]
  147. J Thorac Oncol. 2022 Aug;17(8):1014-1031 [PMID: 35691495]
  148. Chin Med Sci J. 2013 Jun;28(2):82-7 [PMID: 23806369]
  149. Nat Genet. 2009 Jul;41(7):838-42 [PMID: 19483684]
  150. Nat Rev Cancer. 2014 Nov;14(11):747-53 [PMID: 25253389]
  151. Nat Chem Biol. 2017 Apr;13(4):381-388 [PMID: 28135235]
  152. N Engl J Med. 2009 Feb 19;360(8):765-73 [PMID: 19228619]
  153. J Clin Oncol. 2019 Jun 10;37(17):1479-1489 [PMID: 31039052]
  154. J Clin Invest. 2018 Aug 31;128(9):3813-3818 [PMID: 29905573]
  155. Expert Opin Ther Pat. 2024 Apr;34(4):211-229 [PMID: 38742308]
  156. Nat Genet. 2013 Jun;45(6):592-601 [PMID: 23644491]
  157. Nat Genet. 2010 Feb;42(2):181-5 [PMID: 20081860]
  158. Cancer Res. 2021 Dec 15;81(24):6061-6070 [PMID: 34580064]
  159. Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3879-84 [PMID: 22343534]
  160. N Engl J Med. 2009 May 28;360(22):2289-301 [PMID: 19474426]
  161. Cancers (Basel). 2019 Nov 04;11(11): [PMID: 31689915]
  162. Epigenomics. 2024 Mar 26;: [PMID: 38530086]
  163. Blood. 2017 Aug 10;130(6):753-762 [PMID: 28655780]
  164. Am J Cancer Res. 2019 Aug 01;9(8):1682-1694 [PMID: 31497350]
  165. Clin Cancer Res. 2022 May 2;28(9):1948-1965 [PMID: 35135840]
  166. Eur J Med Chem. 2016 Aug 8;118:1-8 [PMID: 27116709]
  167. NPJ Precis Oncol. 2022 Dec 27;6(1):95 [PMID: 36575215]
  168. Lancet Oncol. 2020 Nov;21(11):1433-1442 [PMID: 33035457]
  169. Cell. 2015 Aug 27;162(5):974-86 [PMID: 26317466]

MeSH Term

Humans
Neoplasms
Epigenesis, Genetic
DNA Methylation
Antineoplastic Agents
Gene Expression Regulation, Neoplastic
Epigenomics
Animals

Chemicals

Antineoplastic Agents
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0epigeneticdevelopmentcancerdrugdiscoverydysregulationcancersclinicaltherapeuticsopportunitiesCancermodificationsEpigeneticimportantnexusmaintenancehumanreviewprovidesoverviewunderstandingledinsightsnoveltherapypasttwodecadessignificantstridesmadeeffortstargetingmechanismsleadingsuccessesapprovalarticlewilldiscusscurrenttherapeuticrationaleguidingkeylearningsexperiencesnewhorizontherapy:recentadvanceschallengesemergingepigeneticsDNAcombinationhistonesyntheticlethality

Similar Articles

Cited By